Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy - Morbidity and outcome results

Radiotherapy and Oncology

Volumn 91, Issue 2, 2009, Pages 213-216

  Aaltomaa, Sirpa H ^a   Kataja, Vesa V ^a,b   Lahtinen, Tapani ^a   Palmgren, Jan Erik ^a   Forsell, Tapio ^c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c Kotka Central Hospital   (Finland)

Author keywords

Brachytherapy; Morbidity; Outcome; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MORBIDITY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIOISOTOPE THERAPY; RESIDUAL URINE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MORBIDITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 65449182650     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.12.009     Document Type: Article

References (24)

1. Norderhaug I., Dahl O., Hoisaeter P.A., et al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol 44 (2003) 40-46
2. Ellis R.J., Zhou H., Kim E.Y., et al. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 6 (2007) 16-25
3. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
4. Grimm P.D., Blasko J.C., Sylvester J.E., Meier R.M., and Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
5. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J. Urol. 173 (2005) 1562-1566
6. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
7. Battermann J.J., Boon T.A., and Moerland M.A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71 (2004) 23-28
8. Cosset J.M., Flam T., Thiounn N., et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institute Curie/Cochin Hospital/Necker Hospital group on 809 patients. Int J Radiat Oncol Biol Phys 71 (2008) 1042-1048
9. Guedea F., Aguilo F., Polo A., et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol 80 (2006) 57-61
10. Ash D., Carey B., Bottomley D.M., and Al-Qaisieh B. Long-term outcomes and morbidity after I125 brachytherapy for localised prostate cancer: an early UK series. Clin Oncol (R Coll Radiol) 17 (2005) 127
11. Ash D., Flynn A., Battermann J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57 (2000) 315-321
12. Ash D., Bottomley D., Al-Qaisieh B., Carey B., Gould K., and Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 84 (2007) 135-139
13. Mabjeesh N.J., Chen J., Stenger A., and Matzkin H. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology 70 (2007) 548-553
14. Martens C., Pond G., Webster D., McLean M., Gillan C., and Crook J. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 5 (2006) 9-13
15. Gelblum D.Y., Potters L., Ashley R., Waldbaum R., Wang X.H., and Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59-67
16. Stone N.N., and Stock R.G. Complications following permanent prostate brachytherapy. Eur Urol 41 (2002) 427-433
17. Flam T.A., Peyromaure M., Chauveinc L., et al. Post-brachytherapy transurethral resection of the prostate in patients with localized prostate cancer. J Urol 172 (2004) 108-111
18. Henderson A., Ismail A.K., Cunningham M., et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 16 (2004) 95-104
19. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
20. Stone N.N., and Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69 (2007) 338-342
21. Franca C.A., Vieira S.L., Bernabe A.J., and Penna A.B. The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center. Int Braz J Urol 33 (2007) 752-762 [discussion 762-3]
22. Ciezki J.P., Reddy C.A., Garcia J., et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64 (2006) 512-517
23. Toledano A., Chauveinc L., Flam T., et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure. Cancer Radiother 11 (2007) 105-110
24. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305